newsfilter
← Latest News
GlobeNewswire·

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis